Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform
Ernexa Therapeutics (Nasdaq: ERNA) participated in a Virtual Investor “What This Means” segment on Nov. 6, 2025 to discuss a recently announced partnership with Cellipont Bioservices.
The agreement covers Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for ovarian cancer, into clinical manufacturing and clinical trials. President and CEO Sanjeev Luther represented the company in the segment. The presentation recording is available via the Virtual Investor platform.
Ernexa Therapeutics (Nasdaq: ERNA) ha partecipato a un segmento Virtual Investor “What This Means” il 6 novembre 2025 per discutere di una partnership recentemente annunciata con Cellipont Bioservices.
L’accordo riguarda attività di Engineering, Differentiation e Production (EDP) per avanzare ERNA-101, la terapia cellulare leader di Ernexa per il cancro ovarico, verso la produzione clinica e gli studi clinici. Il presidente e CEO Sanjeev Luther ha rappresentato l’azienda nel segmento. La registrazione della presentazione è disponibile tramite la piattaforma Virtual Investor.
Ernexa Therapeutics (Nasdaq: ERNA) participó en un segmento virtual de inversores “What This Means” el 6 de noviembre de 2025 para hablar sobre una asociación recientemente anunciada con Cellipont Bioservices.
El acuerdo abarca actividades de Engineering, Differentiation y Production (EDP) para impulsar ERNA-101, la terapia celular líder de Ernexa para el cáncer de ovario, hacia la fabricación clínica y ensayos clínicos. El presidente y director ejecutivo Sanjeev Luther representó a la empresa en el segmento. La grabación de la presentación está disponible a través de la plataforma Virtual Investor.
Ernexa Therapeutics (Nasdaq: ERNA)는 2025년 11월 6일에 열린 Virtual Investor의 “What This Means” 세그먼트에 참여하여 Cellipont Bioservices와의 최근 발표 파트너십에 대해 논의했습니다.
계약은 Engineering, Differentiation, and Production (EDP) 활동을 포함하여 ERNA-101, 난소암에 대한 Ernexa의 주력 세포 치료제를 임상 제조 및 임상 시험으로 발전시키는 데 초점을 맞춥니다. 사장 겸 최고경영자 Sanjeev Luther가 세그먼트에서 회사를 대표했습니다. 프레젠테이션 녹화는 Virtual Investor 플랫폼에서 이용 가능합니다.
Ernexa Therapeutics (Nasdaq : ERNA) a participé à un segment Virtuel Investisseur « What This Means » le 6 novembre 2025 pour discuter d’un partenariat récemment annoncé avec Cellipont Bioservices.
L’accord porte sur les activités d’Engineering, Differentiation et Production (EDP) afin de faire progresser ERNA-101, la thérapie cellulaire phare d’Ernexa pour le cancer de l’ovaire, vers la fabrication clinique et les essais cliniques. Le président et PDG Sanjeev Luther a représenté l’entreprise lors du segment. L’enregistrement de la présentation est disponible via la plateforme Virtual Investor.
Ernexa Therapeutics (Nasdaq: ERNA) nahm an einem virtuellen Investoren-Segment „What This Means“ am 6. November 2025 teil, um eine kürzlich angekündigte Partnerschaft mit Cellipont Bioservices zu erörtern.
Die Vereinbarung deckt Aktivitäten in Engineering, Differentiation und Production (EDP) ab, um ERNA-101, Ernexas führende Zelltherapie gegen Eierstockkrebs, in die klinische Herstellung und klinische Studien voranzubringen. Präsident und CEO Sanjeev Luther vertrat das Unternehmen in dem Segment. Die Aufzeichnung der Präsentation ist über die Virtual Investor-Plattform verfügbar.
Ernexa Therapeutics (Nasdaq: ERNA) شاركت في فقرة استثمارية افتراضية بعنوان “What This Means” في 6 نوفمبر 2025 لمناقشة شراكة أعلنت مؤخرًا مع Cellipont Bioservices.
تنص الاتفاقية على أنشطة Engineering, Differentiation, and Production (EDP) لتطوير ERNA-101، العلاج الخلوي الرائد لدى Ernexa لسرطان المبيض، إلى التصنيع السريري والتجارب السريرية. مثل الشركة في تلك الفقرة الرئيس التنفيذي Sanjeev Luther. وتتوفر تسجيلات العرض عبر منصة Virtual Investor.
- None.
- None.
Access the “What This Means” segment here
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor "What This Means" segment.
As part of the segment, Sanjeev Luther, President and CEO of Ernexa, discussed the Company’s recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa's lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
The Virtual Investor “What This Means” segment featuring Ernexa can be accessed here.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com
Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com
FAQ
What did Ernexa (ERNA) announce on Nov. 6, 2025 regarding Cellipont Bioservices?
What is ERNA-101 and what stage will the Cellipont partnership support for ERNA-101?
Who spoke for Ernexa during the Virtual Investor “What This Means” segment on Nov. 6, 2025?
Where can investors watch Ernexa’s Virtual Investor presentation about the Cellipont partnership?
Does the announcement include financial terms or a clinical timeline for ERNA-101?
